IN2014DN09031A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09031A
IN2014DN09031A IN9031DEN2014A IN2014DN09031A IN 2014DN09031 A IN2014DN09031 A IN 2014DN09031A IN 9031DEN2014 A IN9031DEN2014 A IN 9031DEN2014A IN 2014DN09031 A IN2014DN09031 A IN 2014DN09031A
Authority
IN
India
Prior art keywords
tranilast
cocrystal
complex
acid
disclosed
Prior art date
Application number
Inventor
Joanne Holland
Christopher Frampton
Original Assignee
Nuformix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuformix Ltd filed Critical Nuformix Ltd
Publication of IN2014DN09031A publication Critical patent/IN2014DN09031A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/02—Salts; Complexes; Addition compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Mew tranilast complexes and new tranilast cocrystais are disclosed. These include all tranilast nicotinamide complex a 1:1 tranilast nicotinamide cocrystal a 1:1 tranilast saccharin complex a 1:1 tranilast saccharin cocrystal a 1:1 tranilast gentisic acid complex a 1:1 tranilast gentisic acid cocrystal a 1:1 tranilast salicylic acid complex a 1:1 tranilast salicylic acid cocrystal a 1:1 tranilast urea complex a 1:1 tranilast urea cocrystal a 1:1 tranilast 4 amtnoben2oic acid complex a 1:1 tranilast 4 am!nobers2oic acid cocrystal a 1:1 tranilast 2 4 di hydroxybenzoic acid complex and a 1:1 tranilast 2 4 dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed.
IN9031DEN2014 2012-03-30 2013-03-29 IN2014DN09031A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618639P 2012-03-30 2012-03-30
PCT/IB2013/052545 WO2013144916A1 (en) 2012-03-30 2013-03-29 Tranilast compositions and cocrystals

Publications (1)

Publication Number Publication Date
IN2014DN09031A true IN2014DN09031A (en) 2015-05-22

Family

ID=48428556

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9031DEN2014 IN2014DN09031A (en) 2012-03-30 2013-03-29

Country Status (11)

Country Link
US (3) US9512064B2 (en)
EP (1) EP2830590B1 (en)
JP (1) JP6205406B2 (en)
KR (1) KR102093863B1 (en)
CN (1) CN104379130B (en)
AU (1) AU2013239114B2 (en)
BR (1) BR112014024276A2 (en)
CA (1) CA2908440C (en)
ES (1) ES2634993T3 (en)
IN (1) IN2014DN09031A (en)
WO (1) WO2013144916A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014024276A2 (en) * 2012-03-30 2017-08-08 Nuformix Ltd tranilast and co-crystal compositions
EP3268364A1 (en) 2015-03-10 2018-01-17 Vectura Limited Crystalline form of a jak3 kinase inhibitor
ITTO20150243A1 (en) 2015-05-07 2016-11-07 Itt Italia Srl FRICTION MATERIAL, ESPECIALLY FOR THE MANUFACTURE OF A BRAKE PAD, AND ASSOCIATED METHOD OF PREPARATION
WO2017215593A1 (en) * 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
CN106344550A (en) * 2016-09-28 2017-01-25 江苏省人民医院 Application of tranilast to preparation of medicines for treating pneumoconiosis
CN107286210B (en) * 2017-06-19 2020-07-07 昆药集团股份有限公司 Acetyl gastrodin compound and preparation method, preparation and application thereof
US11078155B2 (en) 2018-08-14 2021-08-03 Nuformix Technologies Limited Crystalline tranilast salts and their pharmaceutical use
CN109503415A (en) * 2018-12-28 2019-03-22 药大制药有限公司 A kind of tranilast co-crystal thereof, preparation method and application
EP4077258A1 (en) * 2019-12-20 2022-10-26 Center for Intelligent Research in Crystal Engineering, S.L. Cocrystals of pterostilbene and compositions comprising them
US12226408B2 (en) 2021-08-31 2025-02-18 Cerespir Incorporated Co-crystals
CN119630395A (en) 2022-02-28 2025-03-14 努福米克斯技术有限公司 Compositions and methods for treating idiopathic pulmonary fibrosis
WO2025048416A1 (en) * 2023-08-28 2025-03-06 가톨릭대학교 산학협력단 Composition for preventing radiation-induced inflammatory diseases, and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001072605A (en) * 1999-09-03 2001-03-21 Lion Corp Percutaneous transmucosal absorption enhancer composition
JP2001187728A (en) * 1999-12-28 2001-07-10 Lion Corp Ophthalmic composition
JP2011225626A (en) * 2001-02-01 2011-11-10 Rohto Pharmaceutical Co Ltd Eye lotion
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
CA2548281C (en) * 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
JP2005314229A (en) * 2004-03-31 2005-11-10 Rohto Pharmaceut Co Ltd Tranilast-containing medicine composition
WO2006018997A1 (en) * 2004-08-18 2006-02-23 Medrx Co., Ltd. External preparation
JP2007051089A (en) * 2005-08-18 2007-03-01 Medorekkusu:Kk Preparation for external use
EP1946753A4 (en) * 2005-10-21 2009-05-13 Medrx Co Ltd PREPARATION FOR EXTERNAL APPLICATION COMPRISING A SALT OF A MASTOCYTE DEGRANULATION INHIBITOR COMPRISING A CARBOXYL GROUP WITH AN ORGANIC AMINE
EP2116264B1 (en) * 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
EP2030617A1 (en) 2007-08-17 2009-03-04 Sygnis Bioscience GmbH & Co. KG Use of tranilast and derivatives thereof for the therapy of neurological conditions
CN101683330A (en) * 2008-09-23 2010-03-31 沈阳三川医药科技有限公司 Oral compound pharmaceutic preparation containing tranilast and salbutamol
JP2012526726A (en) * 2009-05-15 2012-11-01 株式会社新日本科学 Intranasal pharmaceutical composition with improved pharmacokinetics
WO2010137681A1 (en) 2009-05-29 2010-12-02 参天製薬株式会社 Prophylactic or therapeutic agent for retinal diseases comprising tranilast, method for prevention or treatment of retinal diseases, and tranilast or pharmaceutically acceptable salt thereof and use thereof
US20110136835A1 (en) * 2009-09-14 2011-06-09 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
JP2011093849A (en) * 2009-10-30 2011-05-12 Kissei Pharmaceutical Co Ltd Easily dissolvable powder inhalant composed of tranilast
CN102665781A (en) 2010-02-02 2012-09-12 泰尔茂株式会社 Bioabsorbable stent
BR112014024276A2 (en) * 2012-03-30 2017-08-08 Nuformix Ltd tranilast and co-crystal compositions

Also Published As

Publication number Publication date
CN104379130B (en) 2018-01-02
BR112014024276A2 (en) 2017-08-08
US20150119428A1 (en) 2015-04-30
US9822066B2 (en) 2017-11-21
US9512064B2 (en) 2016-12-06
CN104379130A (en) 2015-02-25
HK1206619A1 (en) 2016-01-15
AU2013239114A1 (en) 2014-10-30
KR102093863B1 (en) 2020-03-26
WO2013144916A1 (en) 2013-10-03
CA2908440A1 (en) 2013-10-03
ES2634993T3 (en) 2017-10-02
JP2015516951A (en) 2015-06-18
CA2908440C (en) 2021-04-20
US10150729B2 (en) 2018-12-11
JP6205406B2 (en) 2017-09-27
US20180118662A1 (en) 2018-05-03
EP2830590B1 (en) 2017-06-28
AU2013239114B2 (en) 2017-07-20
EP2830590A1 (en) 2015-02-04
KR20140139100A (en) 2014-12-04
US20170158618A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
IN2014DN09031A (en)
SA515360469B1 (en) Heterocyclic compounds for inhibiting glutaminase and their methods of use
MY176488A (en) 1, 4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
MX2020011652A (en) 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions.
IN2014DN10670A (en)
MX368703B (en) A benzoic acid derivative mdm2 inhibitor for the treatment of cancer.
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
BR112012027743A2 (en) cyclopropyl dicarboxamides and analogs exhibiting anticancer and antiproliferative activities
MX2015008957A (en) Fluoro-[1,3]oxazines as bace1 inhibitors.
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
UA109868C2 (en) N -alkyltriazole compounds asr
PH12015502365A1 (en) Bace1 inhibitors
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
WO2013040227A3 (en) Therapeutic compounds
IN2014DN09347A (en)
MX2017005422A (en) Diheteroaryl histone deacetylase inhibitors and their use in therapy.
JOP20190086A1 (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
EA201692298A1 (en) DERIVATIVES OF CARBOXAMIDES
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2014013664A (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexy l) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide.
JO3483B1 (en) 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
MX366309B (en) Pharmaceutical composition for treating inflammation and pain.
MX368640B (en) PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATION and PAIN.
MX342465B (en) METHODS OF TREATING HEMATOLOGIC MALIGNANCIES USING 6-CYCLOHEXYL-1-HYDROXY-4-METHYL-2(1<i>H</i>)-PYRIDONE.
MX2014014817A (en) Compounds for treating inflammation and pain.